MIRACLE
Novel tumor-selective lethal miRNAs for the treatment of head and neck cancer
| Coordinatore | STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
| Nazionalità Coordinatore | Netherlands [NL] |
| Totale costo | 1˙522˙769 € |
| EC contributo | 1˙172˙000 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2013 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2013 |
| Periodo (anno-mese-giorno) | 2013-10-01 - 2015-09-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
STICHTING VU-VUMC
Organization address
address: DE BOELELAAN 1105 contact info |
NL (AMSTERDAM) | coordinator | 7˙500.00 |
| 2 |
INTERNA TECHNOLOGIES BV
Organization address
address: JONKERBOSPLEIN 52 contact info |
NL (NIJMEGEN) | participant | 496˙678.50 |
| 3 |
QUIET THERAPEUTICS LTD
Organization address
address: YAKHIN INDUSTRIAL PARK contact info |
IL (ASHKELON) | participant | 424˙580.00 |
| 4 |
BIOSPRING GESELLSCHAFT FUR BIOTECHNOLOGIE MBH
Organization address
address: ALT-FECHENHEIM 34 contact info |
DE (FRANKFURT AM MAIN) | participant | 228˙241.50 |
| 5 |
LPT LABORATORY OF PHARMACOLOGY AND TOXICOLOGY GMBH & CO KG
Organization address
address: REDDERWEG 8 contact info |
DE (HAMBURG) | participant | 7˙500.00 |
| 6 |
OCTOPLUS NV
Organization address
address: ZERNIKEDREEF 12 contact info |
NL (LEIDEN) | participant | 7˙500.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'MiRacle focuses on the development of a therapeutic formulation for the treatment of head and neck cancer. Head and neck cancer contributes to approximately 5% of all cancers in the Western world. Unfortunately the majority of H&N cancer patients present with advanced stages of disease. These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to improve outcome is therefore urgently awaited.
The goal of MiRacle is the advancement of a therapeutic tumor-killing miRNA formulation towards the clinic by combining two innovative technologies, i.e. therapeutic miRNA and head and neck tumor specific targeted drug delivery. Such a project requires (1) expertise in the therapeutic application of miRNA (InteRNA) and knowledge on the synthesis of biochemical active miRNA (Biospring), (2) expertise in a drug formulation to deliver the therapeutic miRNA into humans (Quiet) and understanding the synthesis of complex drug formulations (Octoplus), plus (3) in depth knowledge of the therapeutic indication, e.g. H&N cancer (VUmc) and skilfulness in toxicity tests that are required for RNA based drug registration (LPT). We believe that this project encompasses all parties that are required to successfully bring a tumor killing miRNA towards registration for first in human testing.'